Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (801)	5/8/2003 1:56:24 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Schleifer today mentioned (If correct and true) that over eleven hundreds subject are still on Axokine open label extension with average 18 months of the treatment time. So, large majority of the antibody positive pts continue with Axokine therapy, and regardless that weight loss benefit is very small. Maybe news is slow in reaching investigators site (they have monthly visit), but something is bit fishy here? The one possible strong reason is desire and difficulty to lose and maintain weight loss. Maybe just idea and hope that drug may help are sufficient good reason to stay on drug??? On another hand Meridia and Xenical are available??? Miljenko